The JAK2 inhibitor, targets the Janus kinase 2 (JAK2) gene, which targets myeloproliferative neoplasms, a variety of blood cancers that cause blood cells to grow abnormally.
The new companion diagnostic test offers both qualitative and quantitative results for use of the JAK2 V617F during clinical trials and aids in identifying patients who benefit from treatment.
Qiagen acclaimed that the new PCR-based companion diagnostic will be marketed and will run on its Rotor-Gene Q instrument.
Qiagen also intends to seek regulatory approval for full automation of the workflow on the QIAsymphony RGQ, a modular sample-to-result automation platform.
Qiagen Personalized Healthcare vice president Stephen Little said the company aims to develop potential for the diagnostic-therapeutic combination to improve the standard of care for patients suffering from blood cancers.
Qiagen gained access to the JAK2 biomarker through an agreement with Ipsogen.
